trending Market Intelligence /marketintelligence/en/news-insights/trending/lazG6vF0-I4U1DSBoHsBcg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

AbbVie's $84B planned Allergan deal survived several rejected offers

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform

AbbVie's $84B planned Allergan deal survived several rejected offers

Months before AbbVie Inc. announced its planned $84.2 billion acquisition of Allergan PLC in June, the two companies' CEOs met to discuss strategy, leading to several rejected offers before the final deal.

SNL ImageAllergan CEO Brent Saunders
Source: Allergan

In a proxy statement released Aug. 12, Allergan revealed that its CEO Brent Saunders spoke with AbbVie CEO Richard Gonzalez in March "to discuss market speculation regarding a variety of potential strategic opportunities Allergan may be considering," at which point Gonzalez said AbbVie would consider exploring a transaction.

The first offer Gonzalez made to acquire the company came at the end of May for between $174 and $178.50 per share, which was 28% to 32% higher than Allergan's value at the time, according to the proxy statement. Saunders and Allergan's M&A committee said they would explore an improved offer.

Gonzalez extended a new offer for $184 per share, saying AbbVie could go as high as $186 per share to acquire Allergan.

On June 11, Saunders once again rejected the offer on behalf of Allergan's board, indicating that a contingent value right — allowing shareholders to gain additional shares — could sweeten the deal.

Gonzalez rejected the contingent value right option, but made the final offer of $188 per share, which consisted of about two-thirds cash and one-third in AbbVie shares — an offer that gained unanimous support from Allergan's board June 16.

Following financial and credit review, the companies announced the deal June 25, which came at a premium of about 44% at the time.